根治性前列腺切除术后初始治疗患者中与可疑18F-DCFPyL前列腺特异性膜抗原正电子发射断层扫描活性相关的临床因素包括前列腺特异性抗原<0.5 ng/mL
该回顾性队列研究纳入2021年7月至2023年2月期间在11家医院系统接受piflufolastat F-18 PSMA PET/CT的患者,中位PSA为0.37 ng/mL,49%的患者至少有一个可疑PSMA亲和病变。PSA<0.2和0.2-0.5 ng/mL患者的扫描阳性率分别为34%和38%。在PSA<0.5 ng/mL患者中,术后放疗史与可疑PSMA活性相关;在总体队列中,年龄、PSA和RP Gleason分级与PSMA阳性相关。
要点
- PSA<0.2 ng/mL患者中超过三分之一存在提示复发的影像学发现。
- PSA<0.5 ng/mL患者中,术后放疗史与可疑PSMA活性相关。
- 低PSA时可考虑行PET-PSMA成像以指导挽救治疗。
核心结论
- PSA<0.2 ng/mL患者中超过三分之一存在提示复发的影像学发现。
- PSA<0.5 ng/mL患者中,术后放疗史与更高的PSMA阳性率相关,且有PSMA亲和远处转移证据的患者中一半接受了转移导向治疗。
- 低PSA时可考虑行PET-PSMA成像以指导挽救治疗。
研究设计与样本
- 回顾性队列研究,纳入2021年7月至2023年2月在11家医院系统接受piflufolastat F-18 PSMA PET/CT的患者。
- PSMA阳性由放射学报告确定,采用单变量和多变量逻辑回归识别与可疑PSMA活性相关的因素。
主要发现
- 中位PSA为0.37 ng/mL(IQR,0.15-1.29 ng/mL),总体上49%的患者至少有一个可疑PSMA亲和病变。
- PSA<0.2和0.2至0.5 ng/mL患者的扫描阳性率分别为34%和38%。
- 在所有患者中,25%(104/415)有盆腔疾病(前列腺床或N1),24%(100/415)有M1疾病。
- 在PSA<0.5 ng/mL患者中,术后放疗与可疑PSMA活性相关。
- 在总体队列中,年龄、PSMA PET/CT时的PSA和RP Gleason分级与PSMA阳性相关;PSA倍增时间、欧洲泌尿外科学会风险和前列腺癌术后风险评估均与可疑PSMA活性相关。
临床怎么用
- 低PSA时可考虑行PET-PSMA成像以指导挽救治疗。
局限性
- 原文未报告局限性
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
PURPOSE: There are limited data on prostate-specific membrane antigen (PSMA) positron emission tomography (PET)/CT for workup of recurrence after radical prostatectomy (RP) at low PSA values. We evaluated a PSMA PET/CT cohort of patients post RP, focusing on patients with PSA < 0.5 ng/mL. MATERIALS AND METHODS: We identified a retrospective cohort who underwent piflufolastat F-18 PSMA PET/CT across an 11-hospital system from July 2021 to February 2023. PSMA positivity was determined by radiology reports. Univariable and multivariable logistic regression identified factors associated with suspicious PSMA activity. RESULTS: Median PSA was 0.37 ng/mL (IQR, 0.15-1.29 ng/mL), with 49% of patients overall having at least 1 suspicious PSMA-avid lesion. Rates of scan positivity among patients with PSA < 0.2 and 0.2 to 0.5 ng/mL were 34% and 38%, respectively. Among all patients, 25% (104/415) had pelvic disease (prostate bed or N1) and 24% (100/415) had M1 disease. Among patients with PSA < 0.5 ng/mL, prior postoperative radiation was associated with suspicious PSMA activity. In the overall cohort, age, PSA at PSMA PET/CT, and RP Gleason grade were associated with PSMA positivity. PSA doubling time, European Association of Urology risk, and Cancer of the Prostate Risk Assessment Postsurgical were all associated with suspicious PSMA activity. CONCLUSIONS: Over one-third of patients with PSAs < 0.2 ng/mL had imaging findings concerning for recurrence. Prior postoperative radiation was associated with higher rates of PSMA positivity among patients with PSA < 0.5 ng/mL, and half of patients with evidence of PSMA-avid distant metastatic disease underwent metastasis-directed therapy. PET-PSMA imaging at low PSAs can be considered to inform salvage therapies.
引用
- Li EV, Bennett R, Ho A, et al. Clinical Factors Associated With Suspicious 18F-DCFPyL Prostate-Specific Membrane Antigen Positron Emission Tomography Activity in Patients Initially Managed With Radical Prostatectomy Including Prostate-Specific Antigen < 0.5 ng/mL. J Urol. 2024. PMID: 39423052. doi:10.1097/JU.0000000000004298
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。